Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

535 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Refractory testicular germ cell tumors are highly sensitive to the second generation DNA methylation inhibitor guadecitabine.
Albany C, Hever-Jardine MP, von Herrmann KM, Yim CY, Tam J, Warzecha JM, Shin L, Bock SE, Curran BS, Chaudhry AS, Kim F, Sandusky GE, Taverna P, Freemantle SJ, Christensen BC, Einhorn LH, Spinella MJ. Albany C, et al. Among authors: einhorn lh. Oncotarget. 2017 Jan 10;8(2):2949-2959. doi: 10.18632/oncotarget.13811. Oncotarget. 2017. PMID: 27936464 Free PMC article.
Management of stage I testicular germ cell tumours.
Chovanec M, Hanna N, Cary KC, Einhorn L, Albany C. Chovanec M, et al. Nat Rev Urol. 2016 Nov;13(11):663-673. doi: 10.1038/nrurol.2016.164. Epub 2016 Sep 13. Nat Rev Urol. 2016. PMID: 27618772 Review.
Long-term toxicity of cisplatin in germ-cell tumor survivors.
Chovanec M, Abu Zaid M, Hanna N, El-Kouri N, Einhorn LH, Albany C. Chovanec M, et al. Among authors: einhorn lh. Ann Oncol. 2017 Nov 1;28(11):2670-2679. doi: 10.1093/annonc/mdx360. Ann Oncol. 2017. PMID: 29045502 Free PMC article. Review.
Randomized, double-blind, placebo-controlled, phase III cross-over study evaluating the oral neurokinin-1 antagonist aprepitant in combination with a 5HT3 receptor antagonist and dexamethasone in patients with germ cell tumors receiving 5-day cisplatin combination chemotherapy regimens: a hoosier oncology group study.
Albany C, Brames MJ, Fausel C, Johnson CS, Picus J, Einhorn LH. Albany C, et al. Among authors: einhorn lh. J Clin Oncol. 2012 Nov 10;30(32):3998-4003. doi: 10.1200/JCO.2011.39.5558. Epub 2012 Aug 20. J Clin Oncol. 2012. PMID: 22915652 Clinical Trial.
535 results